TO USE
Apply liberally before sun exposure and as needed. Children under 6 months of age: ask a doctor. Reapply frequently, and after towel drying, swimming or perspiring.
Apply liberally before sun exposure and as needed. Children under 6 months of age: ask a doctor. Reapply frequently, and after towel drying, swimming or perspiring.
For external use only. Keep out of eyes. Rinse with water to remove.
Stop use and ask a doctor if rash or irritation develops and lasts.
Keep out of reach of children. If swallowed, get medical help right away.
HOMOSALATE 10.0% • OCTISALATE 5.0% • AVOBENZONE 3.0% • OCTOCRYLENE 2.7%
WATER • BUTYLENE GLYCOL • ISONONYL ISONONANDATE • BUTYLOCTYL SALICYLATE • TRIACONTANYL PVP • POLYESTER-8 • SILICA • ROSMARINUS OFFICINALIS (ROSEMARY) EXTRACT • PERILLA OCYMOIDES LEAF EXTRACT • STEARYL DIMETHICONE • CAFFEINE • PLANKTON EXTRACT • SUCROSE • HYDROGENATED LECITHIN • POTASSIUM CETYL PHOSPHATE • LAURDIMONIUM HYDROXYPROPYL HYDROLYZED SOY PROTEIN • PEG-100 STEARATE • CETYL ALCOHOL • POLYETHYLENE • ACRYLIC ACID/VP CROSSPOLYMER • VP/EICOSENE COPOLYMER • TOCOPHERYL ACETATE • TROMETHAMINE • SODIUM RNA • ALOE BARBADENSIS POWDER • PHOSPHOLIPIDS • LECITHIN • MAGNESIUM ASCORBYL PHOSPHATE • SODIUM HYALURONATE • HYDROXYPROPYL METHYLCELLULOSE • C1-8 ALKYL TETRAHYDROXYCYCLOHEXANOATE • HYDROXYETHYLCELLULOSE • ASCORBYL TOCOPHERYL MALEATE • MALTODEXTRIN • CAPRYLYL GLYCOL • HEXYLENE GLYCOL • NORDIHYDROGUAIARETIC ACID • FERULIC ACID • DISODIUM EDTA • PHENOXYETHANOL • CHLORPHENESIN • MICA [ILN34995]
CLINIQUE LABORATORIES, DIST. NEW YORK, N.Y. 10022
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 49527-735-01 | 2019-11-13 | C162847 | 48780-1 | 97449f38-d05e-f6ea-e053-dbdaa90aa703 | CLINIQUE SPF 15 with SolarSmart |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 49527-735-01 | CLINIQUE SPF 15 with SOLAR SMART ADVANCED PROTECTION | 150 mL in 1 BOTTLE | CREAM | 150 | 1 | |
| 49527-735-01 | CLINIQUE SPF 15 with SOLAR SMART ADVANCED PROTECTION | 1 in 1 CARTON | CREAM | 1 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 49527-735 | CLINIQUE SPF 15 WITH SOLAR SMART ADVANCED PROTECTION (HOMOSALATE, OCTISALATE, AVOBENZONE, AND OCTOCRYLENE) CREAM [CLINIQUE LABORATORIES INC.] | 1 | Legacy NDC, 2 package rows | 20120807_340c82a5-bbf5-4528-bb25-51aa267f3b8a.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| avobenzone | ACTIVE INGREDIENT | G63QQF2NOX | 1 | |
| homosalate | ACTIVE INGREDIENT | V06SV4M95S | 1 | |
| octisalate | ACTIVE INGREDIENT | 4X49Y0596W | 1 | |
| octocrylene | ACTIVE INGREDIENT | 5A68WGF6WM | 1 | |
| avobenzone | ACTIVE MOIETY | G63QQF2NOX | 1 | |
| homosalate | ACTIVE MOIETY | V06SV4M95S | 1 | |
| octisalate | ACTIVE MOIETY | 4X49Y0596W | 1 | |
| octocrylene | ACTIVE MOIETY | 5A68WGF6WM | 1 | |
| .alpha.-tocopherol acetate | INACTIVE INGREDIENT | 9E8X80D2L0 | 1 | |
| butylene glycol | INACTIVE INGREDIENT | 3XUS85K0RA | 1 | |
| butyloctyl salicylate | INACTIVE INGREDIENT | 2EH13UN8D3 | 1 | |
| caffeine | INACTIVE INGREDIENT | 3G6A5W338E | 1 | |
| caprylyl glycol | INACTIVE INGREDIENT | 00YIU5438U | 1 | |
| cetyl alcohol | INACTIVE INGREDIENT | 936JST6JCN | 1 | |
| chlorphenesin | INACTIVE INGREDIENT | I670DAL4SZ | 1 | |
| edetate disodium | INACTIVE INGREDIENT | 7FLD91C86K | 1 | |
| ferulic acid | INACTIVE INGREDIENT | AVM951ZWST | 1 | |
| hexylene glycol | INACTIVE INGREDIENT | KEH0A3F75J | 1 | |
| high density polyethylene | INACTIVE INGREDIENT | UG00KM4WR7 | 1 | |
| hyaluronate sodium | INACTIVE INGREDIENT | YSE9PPT4TH | 1 | |
| isononyl isononanoate | INACTIVE INGREDIENT | S4V5BS6GCX | 1 | |
| magnesium ascorbyl phosphate | INACTIVE INGREDIENT | 0R822556M5 | 1 | |
| maltodextrin | INACTIVE INGREDIENT | 7CVR7L4A2D | 1 | |
| masoprocol | INACTIVE INGREDIENT | 7BO8G1BYQU | 1 | |
| mica | INACTIVE INGREDIENT | V8A1AW0880 | 1 | |
| peg-100 stearate | INACTIVE INGREDIENT | YD01N1999R | 1 | |
| perilla frutescens leaf | INACTIVE INGREDIENT | T4L5881Y68 | 1 | |
| phenoxyethanol | INACTIVE INGREDIENT | HIE492ZZ3T | 1 | |
| potassium cetyl phosphate | INACTIVE INGREDIENT | 03KCY6P7UT | 1 | |
| rosemary | INACTIVE INGREDIENT | IJ67X351P9 | 1 | |
| silicon dioxide | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 | |
| sucrose | INACTIVE INGREDIENT | C151H8M554 | 1 | |
| triacontanyl pvp (wp-660) | INACTIVE INGREDIENT | N0SS3Q238D | 1 | |
| tromethamine | INACTIVE INGREDIENT | 023C2WHX2V | 1 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 49527-735 | 49527-735-01 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| sucrose | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| phenoxyethanol | PHENOXYETHANOL | HIE492ZZ3T | LOTION / TOPICAL | 1 %w/w | ||
| sucrose | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| sucrose | SUCROSE | C151H8M554 | LOZENGE / TRANSMUCOSAL | 1255 mg | ||
| sucrose | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| .alpha.-tocopherol acetate | .ALPHA.-TOCOPHEROL ACETATE | 9E8X80D2L0 | FILM / BUCCAL | 0.09 mg | ||
| tromethamine | TROMETHAMINE | 023C2WHX2V | SOLUTION / URETHRAL | 0.12 %w/v | ||
| maltodextrin | MALTODEXTRIN | 7CVR7L4A2D | FILM, SOLUBLE / ORAL | 19 mg | ||
| sucrose | SUCROSE | C151H8M554 | TABLET / SUBLINGUAL | 109 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | POWDER, FOR SUSPENSION / ORAL | 285 mg | ||
| maltodextrin | MALTODEXTRIN | 7CVR7L4A2D | POWDER, FOR SUSPENSION / ORAL | 8000 mg | ||
| high density polyethylene | HIGH DENSITY POLYETHYLENE | UG00KM4WR7 | CAPSULE, EXTENDED RELEASE / ORAL | 4.53 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | TABLET, FILM COATED / ORAL | 4 mg | ||
| tromethamine | TROMETHAMINE | 023C2WHX2V | INJECTION, SOLUTION / INTRAVENOUS | 300 mg | ||
| sucrose | SUCROSE | C151H8M554 | INJECTION / INTRAVENOUS | 1950 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | SYSTEM / TOPICAL | 126 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INFILTRATION | 6 mg | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, SOLUBLE / ORAL | 2 mg | ||
| tromethamine | TROMETHAMINE | 023C2WHX2V | SUSPENSION/ DROPS / OPHTHALMIC | ADJ PH | ||
| tromethamine | TROMETHAMINE | 023C2WHX2V | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 6.06 mg | ||
| sucrose | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | 9.4 %w/v | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | SOLUTION / RESPIRATORY (INHALATION) | 43 mg | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 336 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | SYRUP / ORAL | 40 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | GEL / TRANSDERMAL | 1 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | AEROSOL, FOAM / TOPICAL | 0.05 %w/w | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INTRAVASCULAR | 0.48 mg | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED PELLETS / ORAL | 69 mg | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, DELAYED RELEASE / ORAL | 40 mg | ||
| sucrose | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| high density polyethylene | HIGH DENSITY POLYETHYLENE | UG00KM4WR7 | TABLET, DELAYED RELEASE / ORAL | NA | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION / ORAL | 30 mg | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, EXTENDED RELEASE / ORAL | 450 mg | ||
| sucrose | SUCROSE | C151H8M554 | INJECTION / SUBCUTANEOUS | 47.75 mg | ||
| sucrose | SUCROSE | C151H8M554 | LOZENGE / BUCCAL | NA | ||
| sucrose | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| sucrose | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| high density polyethylene | HIGH DENSITY POLYETHYLENE | UG00KM4WR7 | PASTE / DENTAL | 60 mg | ||
| tromethamine | TROMETHAMINE | 023C2WHX2V | INJECTION, SOLUTION / INTRAVASCULAR | 225 mg | ||
| .alpha.-tocopherol acetate | .ALPHA.-TOCOPHEROL ACETATE | 9E8X80D2L0 | TABLET / ORAL | 0.5 mg | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER, FOR SOLUTION / ORAL | 280 mg | ||
| tromethamine | TROMETHAMINE | 023C2WHX2V | INJECTION / INTRAMUSCULAR | 437 mg | ||
| sucrose | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| tromethamine | TROMETHAMINE | 023C2WHX2V | GEL / TRANSDERMAL | 10 mg | ||
| hexylene glycol | HEXYLENE GLYCOL | KEH0A3F75J | OINTMENT / TOPICAL | 12 %w/w | ||
| tromethamine | TROMETHAMINE | 023C2WHX2V | INJECTION, SOLUTION / INTRA-ARTERIAL | 300 mg | ||
| tromethamine | TROMETHAMINE | 023C2WHX2V | SOLUTION / OPHTHALMIC | 0.75 %w/v | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / SUBLINGUAL | 10 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION / AURICULAR (OTIC) | 0.01 %w/v | ||
| sucrose | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg | ||
| high density polyethylene | HIGH DENSITY POLYETHYLENE | UG00KM4WR7 | TABLET / ORAL | 50 mg | ||
| tromethamine | TROMETHAMINE | 023C2WHX2V | INJECTION / INTRA-ARTERIAL | 562 mg | ||
| cetyl alcohol | CETYL ALCOHOL | 936JST6JCN | OINTMENT / TOPICAL | 7 %w/w | ||
| tromethamine | TROMETHAMINE | 023C2WHX2V | CAPSULE / ORAL | 30 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION/ DROPS / OPHTHALMIC | 1 mg | ||
| silicon dioxide | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, DELAYED RELEASE PARTICLES / ORAL | 170 mg | ||
| sucrose | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| sucrose | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| edetate disodium | EDETATE DISODIUM | 7FLD91C86K | TABLET / ORAL | 100 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ccaf35c2-e800-4f09-9881-55decb422123 | 340c82a5-bbf5-4528-bb25-51aa267f3b8a | 2012-08-06 | Warnings | ccaf35c2-e800-4f09-9881-55decb422123 340c82a5-bbf5-4528-bb25-51aa267f3b8a |
Adverse event summaries are temporarily unavailable. Other product information remains available.